The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Recurrent emergence and transmission of a SARS-CoV-2 spike deletion H69/V70
Open accessPreprint — published as 10.1016/j.celrep.2021.109292
Abstract
SARS-CoV-2 amino acid replacements in the receptor binding domain (RBD) occur relatively frequently and some have a consequence for immune recognition. Here we report recurrent emergence and significant onward transmission of a six-nucleotide out of frame deletion in the S gene, which results in loss of two amino acids: H69 and V70. We report that in human infections ΔH69/V70 often co-occurs with the receptor binding motif amino acid replacements N501Y, N439K and Y453F, and in the latter two cases has followed the RBD mutation. One of the ΔH69/V70+ N501Y lineages, now known as B.1.1.7, has undergone rapid expansion and includes eight S gene mutations: RBD (N501Y and A570D), S1 (ΔH69/V70 and Δ144) and S2 (P681H, T716I, S982A and D1118H). In vitro , we show that ΔH69/V70 does not reduce serum neutralisation across multiple convalescent sera. However, ΔH69/V70 increases infectivity and is associated with increased incorporation of cleaved spike into virions. ΔH69/V70 is able to compensate for small infectivity defects induced by RBD mutations N501Y, N439K and Y453F. In addition, replacement of H69 and V70 residues in the B.1.1.7 spike reduces its infectivity and spike mediated cell-cell fusion. Based on our data ΔH69/V70 likely acts as a permissive mutation that allows acquisition of otherwise deleterious immune escape mutations. Enhanced surveillance for the ΔH69/V70 deletion with and without RBD mutations should be considered as a global priority not only as a marker for the B.1.1.7 variant, but potentially also for other emerging variants of concern. Vaccines designed to target the deleted spike protein could mitigate against its emergence as increased selective forces from immunity and vaccines increase globally. Highlights: ΔH69/V70 is present in at least 28 SARS-CoV-2 lineages ΔH69/V70 does not confer escape from convalescent sera ΔH69/V70 increases spike infectivity and compensates for RBD mutations ΔH69/V70 is associated with greater spike cleavage B.1.1.7 requires ΔH69/V70 for optimal spike cleavage and infectivity
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although distinct, the variants share common characteristics, including known escape mutations that were previously identified under antibody pressure selection in vitro 2,3,[13][14][15][16][17] .”
From Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies (2021) · cites this paper as [2]
In the citing paper
“The B.1.1.7 variant emerged in the United Kingdom, the B.1.351variant (also termed 501Y.V2) in South Africa and the P.1 and P.2 lineages in Brazil 2,3,5,9-12 .”
From Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies (2021) · cites this paper as [2]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MAFFT Multiple Sequence Alignment Software Version 7: Improvements in Performance and Usability
Katoh, K., & Standley, D. M. (2013) · Molecular Biology and Evolution · doi:10.1093/molbev/mst010 · Cited by 46,209
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969
ModelFinder: fast model selection for accurate phylogenetic estimates
Kalyaanamoorthy, S., Minh, B. Q., Wong, T. K. F., von Haeseler, A., & Jermiin, L. S. (2017) · Nature Methods · doi:10.1038/nmeth.4285 · Cited by 18,449
IQ-TREE 2: New Models and Efficient Methods for Phylogenetic Inference in the Genomic Era
Minh, B. Q., Schmidt, H. A., Chernomor, O., Schrempf, D., Woodhams, M. D., von Haeseler, A., & Lanfear, R. (2020) · Molecular Biology and Evolution · doi:10.1093/molbev/msaa015 · Cited by 16,873
SWISS-MODEL: homology modelling of protein structures and complexes
Waterhouse, A. M., Bertoni, M., Bienert, S., Studer, G., Tauriello, G., Gumienny, R., Heer, F. T., de Beer, T., Rempfer, C., Bordoli, L., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky427 · Cited by 13,248
I-TASSER: a unified platform for automated protein structure and function prediction
Roy, A., Küçükural, A., & Zhang, Y. (2010) · Nature Protocols · doi:10.1038/nprot.2010.5 · Cited by 6,212
Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, Q., Shi, X., Wang, Q., Zhang, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2180-5 · Cited by 5,983
FastTree: Computing Large Minimum Evolution Trees with Profiles instead of a Distance Matrix
Price, M. N., Dehal, P. S., & Arkin, A. P. (2009) · Molecular Biology and Evolution · doi:10.1093/molbev/msp077 · Cited by 5,602
The proximal origin of SARS-CoV-2
Andersen, K. G., Rambaut, A., Lipkin, W. I., Holmes, E. C., & Garry, R. F. (2020) · Nature Medicine · doi:10.1038/s41591-020-0820-9 · Cited by 5,081
Ultrafast Approximation for Phylogenetic Bootstrap
Minh, B. Q., Nguyen, M. A. T., & von Haeseler, A. (2013) · Molecular Biology and Evolution · doi:10.1093/molbev/mst024 · Cited by 4,844
Flagged first, then by citations
Research works printed but not linked: 4
- Collier, D.A. , Marco, A.D. , Ferreira, I.A.T.M. , Meng, B. , Datir, R. , Walls, A.C. , Kemp S, S.A. , Bassi, J. , Pinto, D. , Fregni, C.S. , et al. (2021b). SARS-CoV-2 B.1.1.7 escape from mRNA vaccine-elicited neutralizing antibodies. medRxiv, 2021.2001.2019.21249840.
- 2011, BioEdit: an important software for molecular biology, GERF Bull Biosci, 2, 60
- 2020, Combined Point-of-Care Nucleic Acid and Antibody Testing for SARS-CoV-2 following Emergence of D614G Spike Variant, Cell Rep Med, 1, 100099, 10.1016/j.xcrm.2020.100099 · DOI
- 2017, GISAID: Global initiative on sharing all influenza data - from vision to reality. Euro surveillance: bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 22, 30494
Cited by
Sorted by citations
Items 201–262 of 262
Computational Analysis Predicts Correlations among Amino Acids in SARS-CoV-2 Proteomes
Broni, E., & Miller, W. A. (2023) · Biomedicines · doi:10.3390/biomedicines11020512 · Cited by 5
Paradigm of immune dysregulation in coronavirus disease-2019 infection
Sahoo, O. S., Pethusamy, K., Nayek, A., Minocha, R., Dhar, R., & Karmakar, S. (2024) · Exploration of Immunology · doi:10.37349/ei.2024.00126 · Cited by 7
Sola‐Campoy, P. J., Buenestado‐Serrano, S., Pérez‐Lago, L., Rodríguez‐Grande, C., Catalán, P., Andrés-Zayas, C., Alcalá, L., Losada, C., Rico-Luna, C., Muñóz, P., et al. (2021) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2021.05.008 · Cited by 5
Gasparo, R. D., Pedotti, M., Simonelli, L., Nickl, P., Muecksch, F., Cassaniti, I., Percivalle, E., Lorenzi, J. C. C., Mazzola, F., Magrì, D., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.01.22.427567 · Cited by 5
Putra, W. F. (2022) · Jurnal Kedokteran Meditek · doi:10.36452/jkdoktmeditek.v28i1.2243 · Cited by 6
SARS-CoV-2 vaccines and their challenges against the variants
Shrestha, U. K. (2021) · Journal of Advances in Internal Medicine · doi:10.3126/jaim.v10i1.37080 · Cited by 4
Whole Genome Sequence Analysis to Identify SARS-CoV-2 Variant in Nepal
Shrestha, R., Katuwal, N., Adhikari, N., Vanaerschot, M., Tamrakar, D., Dhimal, M. L., Gyanwali, P., Bhattarai, S., Madhup, S. K., & Devkota, B. (2021) · Kathmandu University Medical Journal · doi:10.3126/kumj.v19i2.49653 · Cited by 4
Immune dynamics of SARS-CoV-2 virus evolution
Kamat, M., Kurlawala, V., Ghosh, G., & Vaishnav, R. (2022) · International Journal of Molecular and Immuno Oncology · doi:10.25259/ijmio_26_2021 · Cited by 4
Ghobashy, M. M., Alshangiti, D. M., Alkhursani, S. A., Al-Gahtany, S. A., Meganid, A. S., Madani, M., & Kodous, A. S. (2022) · Green Processing and Synthesis · doi:10.1515/gps-2022-0018 · Cited by 4
van der Lubbe, J. E. M., Huber, S. K. R., Vijayan, A., Dekking, L., van Huizen, E., Vreugdenhil, J., Choi, Y., Baert, M. R. M., Boer, K. F.-D., Gil, A. I., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.01.08.425915 · Cited by 4
ddPCR Reveals SARS-CoV-2 Variants in Florida WastewaterPreprint
Gering, E., Colbert, J., Schmedes, S. E., Duncan, G., Lopez, J. V., Motes, J., Weiss, J., Azarian, T., Tekin, O., & Blanton, J. L. (2021) · medRxiv · doi:10.1101/2021.04.08.21255119 · Cited by 4
Unbuttoning the Impact of N501Y Mutant RBD on viral Entry Mechanism: A Computational InsightPreprint
Sharma, T., Baig, M. H., Rahim, M., Dong, J.-J., & Cho, J. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.12.30.424906 · Cited by 4
Exploring COVID-19: Relating the spike protein to infectivity, pathogenicity and Immunogenicity
Nikhra, V. (2021) · International Journal of Clinical Virology · doi:10.29328/journal.ijcv.1001029 · Cited by 3
Notable Variants of SARS-CoV-2
Naji, H. S. (2021) · European Journal of Medical and Health Sciences · doi:10.24018/ejmed.2021.3.2.742 · Cited by 3
Mok, B. W.-Y., Liu, H., Lau, S.-Y., Deng, S., Liu, S., Tam, R. C.-Y., Ng, T. T.-L., Leung, J. S.-L., Wang, P., To, K. K., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.19.440414 · Cited by 3
de Oliveira, M. D. L., de Oliveira, K. M. T., Silva, J. N., Santos, C., Bessa, J., & de Freitas, R. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.09.439181 · Cited by 3
ADAR mediated A-to-I RNA editing affects SARS-CoV-2 characteristics and fuels its evolutionPreprint
Song, Y., He, X., Yang, W., Tang, T., & Zhang, R. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.07.22.453345 · Cited by 3
Rocchigiani, A. M., Luca Ferretti, A., Ledda, A., Nardo, A. D., Floris, M., Bonelli, P., Loi, F., Idda, M. L., Angioi, P. P., Zinellu, S., et al. (2023) · Viruses · doi:10.3390/v15020277 · Cited by 2
The Development of Epitope-Based Recombinant Protein Vaccines against SARS-CoV-2
Khalid, K., Lim, H. X., Hwang, J. S., & Poh, C. L. (2024) · The AAPS Journal · doi:10.1208/s12248-024-00963-1 · Cited by 3
RNA-based vaccines against SARS-CoV-2
Rosales‐Mendoza, S., Wong-Arce, A., & Betancourt-Mendiola, L. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-90248-9.00014-0 · Cited by 2
Hossain, M. E., Rahman, M. M., Alam, M. S., Sarmin, M., Karim, Y., Hasan, M., Hoque, A. F., Hasan, M. M., Rahman, M. Z., Chisti, M. J., et al. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.792514 · Cited by 2
Ramasamy, R. (2023) · International Journal of Microbiology Research · doi:10.4103/ijmr.ijmr_2591_22 · Cited by 2
Epidemiological, clinical and genomic snapshot of the first 100 B.1.1.7 SARS-CoV-2 cases in Madrid
Pérez‐Lago, L., Sola‐Campoy, P. J., Buenestado‐Serrano, S., Pharmacy, P. C., Estévez, A., Technician, V. M. D. L. C., López, M. G., Herránz, M., Suárez‐González, J., Alcalá, L., et al. (2021) · Journal of Travel Medicine · doi:10.1093/jtm/taab044 · Cited by 2
Epidemiology of SARS-CoV-2 and Emergence of UK Variant in Zintan City of Libya
Kammon, A. M., Giweli, A., Erhouma, E. A., Rammah, E., Elusta, A., Knifo, S., Ali, W. R., Benbubaker, W. M., Ebrahim, F. O., & Elarabi, A. (2021) · Open Journal of Epidemiology · doi:10.4236/ojepi.2021.114029 · Cited by 2
CovRadar: Continuously tracking and filtering SARS-CoV-2 mutations for molecular surveillancePreprint
Wittig, A., Miranda, F. M., Hölzer, M., Altenburg, T., Bartoszewicz, J. M., Beyvers, S., Dieckmann, M. A., Genske, U., Giese, S. H., Nowicka, M., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.03.429146 · Cited by 2
Merchant, A., Tania, V. H., Baptiste, M., Ehsan, H., & Kaneko, G. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91172-6.00009-1 · Cited by 1
Aanniz, T., Ouadghiri, M., Bendahou, M. A., Chemao-Elfihri, M. W., Chenaoui, M., DAKKA, H., Allaoui, A., Touzani, O., Benaouda, A., Belefquih, B., et al. (2021) · Microbiology Resource Announcements · doi:10.1128/mra.00027-21 · Cited by 1
Predominant Mutations of SARS-CoV-2: Their Geographical Distribution and Potential Consequences
Ünlü, S., Güçlü, A. Ü., & BAŞUSTAOĞLU, A. C. (2021) · Mediterranean Journal of Infection Microbes and Antimicrobials · doi:10.4274/mjima.galenos.2021.2021.15 · Cited by 1
Current Control Measures for SARS-CoV-2 the Aetiological Agent of COVID-19
Meade, E., Savage, M., & Garvey, M. (2021) · Microbiology & Infectious Diseases · doi:10.33425/2639-9458.1138 · Cited by 1
Emergence and spreading of the largest SARS-CoV-2 deletion in the Delta AY.20 lineage from Uruguay
Panzera, Y., Cortinas, M. N., Marandino, A. E., Calleros, L., Bórmida, V., Goñi, N., Techera, C., Grecco, S., Williman, J., Ramas, V., et al. (2022) · Gene Reports · doi:10.1016/j.genrep.2022.101703 · Cited by 1
SURRAYA TAJ, T. T. (2023) · Russian Law Journal · doi:10.52783/rlj.v11i3.2070 · Cited by 2
Concerns Raised on Blood Group Determinants in Plasma Membrane Interaction of the SARS-CoV-2Preprint
Fiedler, K. (2021) · Preprints.org · doi:10.20944/preprints202103.0460.v1
Diabelko, D., Dvořáčková, M., Dvořáková, M., Forte, G., Čundrle, I., Růžička, F., & Vrbský, J. (2021) · medRxiv · doi:10.1101/2021.05.24.21257365 · Cited by 1
Russell, A., O’Connor, C., Lasek‐Nesselquist, E., Plitnick, J., Kelly, J. P., Lamson, D. M., & George, K. S. (2021) · medRxiv · doi:10.1101/2021.09.14.21262977 · Cited by 1
Concerns Raised on Blood Group Determinants in Plasma Membrane Interaction of the SARS-CoV-2Preprint
Fiedler, K. (2021) · Preprints.org · doi:10.20944/preprints202103.0460.v2 · Cited by 1
Inadvertent Human Mucosal Exposure to SARS-CoV-2 Recombinant S1 Protein Elicits ImmunityPreprint
Carbonell (2021) · Research Square · doi:10.21203/rs.3.rs-249113/v1
Computational methods to predict the mutational landscape of the spike protein
Paci, E., & Ross, J. F. (2021) · Biophysical Journal · doi:10.1016/j.bpj.2021.05.001
SARS-CoV-2 convergent evolution cannot be reliably inferred from phylogenetic analysesPreprint
Jo, Y.-S., Tamuri, A. U., Towers, G. J., & Goldstein, R. A. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.15.444301 · Cited by 1
Delta variant - A new phase of COVID-19 in India
Sreenivas, S. S. (2021) · International Journal of Medical Science · doi:10.14445/23939117/ijms-v8i7p105
Slow vaccination and immunity profile homogeny as a cause of SARS-CoV-2 antigenic drift
Khan, N. (2026) · Open Collections · doi:10.14288/ujemip.v5.203762
Improvement of SARS-CoV-2 macromolecule conformation by algorithmic structural prediction
de Souza, C., Bessa, J. A., de Freitas, R., de Oliveira, M. D. L., & Mota, K. (2021) · Latin American Computer Conference (CLEI) · doi:10.1109/clei53233.2021.9640088
Concerns Raised on Blood Group Determinants in Plasma Membrane Interaction of the SARS-CoV-2Preprint
Fiedler, K. (2021) · Preprints.org · doi:10.20944/preprints202103.0460.v3
Sola‐Campoy, P. J., Buenestado‐Serrano, S., Pérez‐Lago, L., Rodríguez‐Grande, C., Catalán, P., Andrés-Zayas, C., Alcalá, L., Losada, C., Rico-Luna, C., Muñóz, P., et al. (2022) · Enfermedades infecciosas y microbiologia clinica (English ed ) · doi:10.1016/j.eimce.2021.05.015
3D structural prediction, analysis and validation of Sars-Cov-2 protein molecules
de Souza, C., de Oliveira, M. D. L., Bessa, J. A., Mota, K., & de Freitas, R. (2022) · CLEI electronic journal · doi:10.19153/cleiej.25.2.9
SARS-CoV-2 Variant Surveillance in Genomic Medicine Era
Diaconu, C. C., Pitica, I. M., Chivu‐Economescu, M., Necula, L. G., Botezatu, A., Iancu, I. V., Neagu, A. I., Radu, E. L., Matei, L., Ruță, S. M., et al. (2022) · Infectious diseases · doi:10.5772/intechopen.107137
Ji, C., & Shao, J. (2022) · Research Square · doi:10.21203/rs.3.rs-2062759/v1
Perspective Chapter: Real-Time Genomic Surveillance for SARS-CoV-2 on Center Stage
Paz, M., Moreno, P., & Moratorio, G. (2022) · Infectious diseases · doi:10.5772/intechopen.107842
Ji, C., & Shao, J. (2022) · Research Square · doi:10.21203/rs.3.rs-2062759/v2
Emergence of SARS CoV-2 Variant B.1.1.7 in a Pandemic Hospital
Bilgin, M., Taşkın, M. H., Özgen, E., & Yavuz, D. (2022) · Flora the Journal of Infectious Diseases and Clinical Microbiology · doi:10.5578/flora.20229607
Perspective on Accuracy of Past SARS-CoV-2 Evolutionary Predictions
Blais-Savoie, J. (2023) · Journal of Undergraduate Life Sciences · doi:10.33137/juls.v16i1.39995
Detection of SARS-CoV-2 Post COVID-19 Vaccination in Health Workers in the COVID-19 Isolation Room
Kusumawati, R. L., Hasibuan, M., & Joli, J. S. (2023) · ABDIMAS TALENTA Jurnal Pengabdian Kepada Masyarakat · doi:10.32734/abdimastalenta.v8i1.10273
Tracking SARS-CoV-2 variants in Kurdistan Region of Iraq.
Mohamedsalih, P. M., Salih, K. J., Kareem, B. O., & Sabir, D. K. (2023) · ZANCO Journal of Pure and Applied Sciences · doi:10.21271/zjpas.35.5.12
Ji, C., & Shao, J. J. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4692772
Analyzing the Impact of Concomitant COVID-19 Infection on Outcomes in Trauma Patients
Rafaqat, W., Abiad, M., Lagazzi, E., Argandykov, D., Proaño-Zamudio, J. A., Velmahos, G. C., Hwabejire, J. O., Parks, J. J., Luckhurst, C. M., & DeWane, M. P. (2024) · The American Surgeon · doi:10.1177/00031348241246176
Different variants of SARS-CoV-2
Samanta, A., Hassan, M. S., Nasrin, T., Alam, S. S. M., Jamil, Z., Buttar, H. S., Ali, S., & Hoque, M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95650-5.00053-7
Mohsenzadeh, A., Pourasgar, S., Borji, S., Bavari, S., Moghadam, E. E., Tanha, H. R., Mohsenzadeh, H., Kamali, K., Moghadam, Z. B., & Sabati, H. (2022) · Journal of Current Biomedical Reports · doi:10.61186/jcbior.3.3.172
Jena, A. B., Dash, U. C., & Duttaroy, A. K. (2025) · The Protein Journal · doi:10.1007/s10930-025-10309-1
Caractérisation de la diversité génétique de SARS-CoV-2 dans des échantillons cliniques
Bader, W. (2022) · theses.fr (ABES) · doi:10.70675/09aee16fz8ab8z4823za3d0z6866bfbc0a6c
Étude de la réponse humorale lors de l'infection par le SARS-CoV-2
Marot, S. (2023) · theses.fr (ABES) · doi:10.70675/7d41e61azd818z408dzb17cz1c0cf0738b83
Metadata
- Authors
- Kemp, S. A., Meng, B., Ferriera, I. A., Datir, R., Harvey, W. T., Papa, G., Lytras, S., Collier, D. A., Mohamed, A., Gallo, G., Thakur, N., The COVID-19 Genomics UK (COG-UK) Consortium, Carabelli, A. M., Kenyon, J. C., Lever, A. M., De Marco, A., Saliba, C., Culap, K., Cameroni, E., Piccoli, L., Corti, D., James, L. C., Bailey, D., Robertson, D. L., & Gupta, R. K.
- Affiliations
- University of Cambridge (GB)
- University of Glasgow (GB)
- MRC Laboratory of Molecular Biology (GB)
- MRC University of Glasgow Centre for Virus Research (GB)
- The Pirbright Institute (GB)
- National University of Singapore (SG)
- Vir Biotechnology (Switzerland) (CH)
- Corresponding author
- Gupta, Ravindra K.
- ORCID
- Kemp, Steven A
- Meng, Bo
- Datir, Rawlings
- Harvey, William T
- Papa, Guido
- Lytras, Spyros
- Collier, Dami A
- Gallo, Giulia
- Thakur, Nazia
- Carabelli, Alessandro M
- Kenyon, Julia C
- Lever, Andrew M
- Saliba, Christian
- Culap, Katja
- Cameroni, Elisabetta
- Piccoli, Luca
- Corti, Davide
- James, Leo C
- Bailey, Dalan
- Robertson, David L
- Gupta, Ravindra K.
- Venue
- bioRxiv (Cold Spring Harbor Laboratory)
- Publisher
- openRxiv
- Published
- 2020-12-14
- OpenAlex
- W3112108776
- Cited by
- 252
- References
- 68
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 6 · 2023: 13 · 2022: 47 · 2021: 181 · 2020: 3
- Type
- posted content
- Language
- en
- Open access
- green
- doi.org
- Licence
- Locations
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by)
- SSRN Electronic Journal (acceptedVersion)
- Apollo (University of Cambridge) (submittedVersion, cc-by)
- Apollo (cc-by)
- Funders
- Bill and Melinda Gates Foundation (OPP 1175094)
- NHS Blood and Transplant (WPA15‐02)
- Wellcome Trust (WT108082AIA, DEL-15-006)
- UK Research and Innovation (MC_PC_19027)
- National Institute for Health and Care Research
- University of Cambridge
- Rosetrees Trust
- Cambridge University Hospitals
- Medical Research Council (MC_UU_12014, MC UU 12014/12, MR/P008801/1, MR/R024758/1, 1201412)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
- Keywords
- SARS-CoV-2, receptor-binding domain mutations, N501Y, immune evasion, neutralizing antibodies, viral infectivity, cell-cell fusion, variants of concern, S gene mutations, vaccine design, Omicron BA.1, BA.2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
